MEDITE Cancer Diagnostics, Inc. is a medical technology company which engages in cancer diagnostics instruments and consumables for histology and cytology laboratories. It specializes in developing, manufacturing, and marketing of molecular biomarkers premium medical devices and consumables for detection, risk assessment and diagnosis of cancer, precancerous conditions, and related diseases. It operates through the following segments: United States, Germany, and Poland. The company was founded in December 1998 and is headquartered in Orlando, FL.
Company profile
Ticker
MDIT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Ampersand Medical Corp, Bell National Corp, CytoCore Inc, Molecular Diagnostics Inc
SEC CIK
Corporate docs
IRS number
364296006
MDIT stock data
Latest filings (excl ownership)
8-K
W. Austin Lewis IV, Chairman of the Board
6 May 19
8-K
Other Events
23 Apr 19
15-12G/A
Securities registration termination (amended)
2 Apr 19
NT 10-K
Notice of late annual filing
1 Apr 19
15-12G
Securities registration termination
22 Mar 19
8-K
Departure of Directors or Certain Officers
18 Mar 19
PRE 14C
Preliminary information
28 Feb 19
8-K
Bankruptcy or Receivership
3 Jan 19
8-K
Entry into a Material Definitive Agreement
6 Dec 18
10-Q
2018 Q3
Quarterly report
14 Nov 18
Latest ownership filings
SC 13G/A
Medite Cancer Diagnostics, Inc.
2 Nov 18
4
JOHN H ABELES
23 Oct 18
4
William Austin IV Lewis
19 Oct 18
4
William Austin IV Lewis
30 Jul 18
4
Rump Stephen L. Von
30 Jul 18
3
Rump Stephen L. Von
20 Jul 18
4
William Austin IV Lewis
12 Jul 18
4
JOHN H ABELES
10 Jul 18
4
William Austin IV Lewis
5 Jul 18
4
GREGORY FORTUNOFF
8 May 18